Brexpiprazole
Brand names: Rexulti
At a glance
- Medicare prescriptions, 2024
- 456,374
- Medicare drug cost
- $628.4M
- Average cost per prescription
- $1,377
- Clinicians who prescribed it
- 16,018
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use:
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatric Nurse Practitioners 26.6%
- Psychiatry 22.0%
- Nurse Practitioners 14.8%
- Family Medicine 12.6%
- Internal Medicine 10.4%
- Physician Assistants 5.6%
- Neurology 3.4%
- Geriatric Medicine 1.3%
- Child & Adolescent Psychiatry 1.0%
- General Practice 0.5%
- Hospitalist 0.4%
- Addiction Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 131% from 2019 to 2024.
Biggest change by state since 2019
- Georgia +223%
- New York +178%
- Florida +169%
- Tennessee +149%
- Pennsylvania +147%
- Massachusetts (smallest change) +77%
- Ohio (smallest change) +89%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ajanta Pharma USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.25 mg | brown round tablet, 6 mm | BX 6 |
| 0.5 mg | orange round tablet, 6 mm | BX 5 |
| 1 mg | yellow round tablet, 6 mm | BX 1 |
| 2 mg | green round tablet, 6 mm | BX 2 |
| 3 mg | pink round tablet, 6 mm | BX 3 |
| 4 mg | white round tablet, 6 mm | BX 4 |
Otsuka America Pharmaceutical, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.25 mg | brown round tablet, 6 mm | BRX AND 0 25 |
| 0.5 mg | orange round tablet, 6 mm | BRX AND 0 5 |
| 1 mg | yellow round tablet, 6 mm | BRX AND 1 |
| 2 mg | green round tablet, 6 mm | BRX AND 2 |
| 3 mg | purple round tablet, 6 mm | BRX AND 3 |
| 4 mg | white round tablet, 6 mm | BRX AND 4 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | yellow round tablet, 6 mm | BRX AND 1 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $11.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Otsuka America Pharmaceutical, Inc. $9.1M
- Lundbeck LLC $1.5M
- Otsuka Pharmaceutical Development & Commercialization, Inc. $314,643
- H. Lundbeck A S $181,903
- Otsuka Pharmaceutical Co., LTD. $121,041
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.